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Abstract
Background: The majority of patients with multidrug-resistant tuberculosis (MDR-TB) in South Africa are co-infected
with HIV, but the radiographic features of MDR-TB and their relationship with time to sputum culture conversion in the
antiretroviral therapy era have not been described.
Methods: We reviewed baseline chest radiographs for 56 patients with MDR-TB from a rural area of South Africa.
We analyzed the association of cavities, consolidation, pleural effusion and hilar lymphadenopathy with time to
sputum culture conversion, adjusting for HIV status, baseline sputum smear and CD4 count.
Results: Of the 56 subjects, 49 (88%) were HIV-positive, with a median CD4 count of 136 cells/mm3 (IQR 65-249).
Thirty-two (57%) patients were sputum smear positive. Twenty-two (39%) patients had a cavity and 37 (66%)
patients had consolidations. Cavitary disease and consolidations were each associated with longer time to culture
conversion on bivariate analysis but not after adjusting for sputum smear status (aORs 1.79 [0.94-3.42] and 1.09
[0.67-1.78], respectively). Positive baseline sputum smear remained independently associated with longer time to
conversion (aOR 3.45 [1.39-8.59]). We found no association between pleural effusion or hilar lymphadenopathy and
time to conversion. Seventy-nine percent of patients were cured at the end of treatment.
Conclusions: Despite high rates of HIV co-infection and advanced immunodeficiency, the majority of patients had
severe pathology on baseline chest radiograph. Nevertheless, culture conversion rates were high and treatment
outcomes were favorable. Cavitation and consolidation do not appear to have an independent association with time
to culture conversion beyond that of baseline sputum smear status.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB), defined as
resistance to at least isoniazid and rifampin, remains a growing
threat to TB control worldwide and is associated with high
mortality—especially in the setting of HIV co-infection [1,2].
Treatment for MDR-TB is more expensive, more toxic and less
effective than treatment for drug-susceptible TB, and must be
given for approximately two years. Given the significant human
and financial resources required for proper management of
MDR-TB, several studies have attempted to identify clinical or
biological risk factors for poor outcome, so that practitioners
might stratify patients at the start of treatment and tailor their
therapy accordingly [3,4]. Chest radiography, which is rapid
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and inexpensive, could potentially identify those with severe
disease at the time of treatment initiation.
Even in resource-limited settings, most countries providing
MDR-TB treatment have access to chest radiography, but the
correlation of radiographic findings with clinical disease severity
and its utility in predicting TB treatment outcomes remains
unclear. Although previous studies have examined the
relationship between chest radiograph findings and response to
TB treatment, drug-resistance and HIV co-infection may
complicate this relationship. Decreased time to sputum culture
conversion has been an useful early predictor of successful
final treatment outcome and several studies have found that
cavitary disease on chest radiograph is associated with a
longer time to culture conversion in drug-susceptible TB [5].
Notably, however, these and other studies have also shown
that while patients with HIV are less likely to have cavitary
disease, they are more likely to have poor outcomes from TB
[6–8]. In addition, most studies examining predictors of sputum
culture conversion were done in patients with drug-susceptible
TB [9–11].
Among the few studies in MDR-TB, Holtz et al, found that
cavitary disease on baseline chest radiograph was associated
with a longer time to sputum culture conversion [12], but this
study had only one patient (<1%) who was HIV-positive [13].
Whether baseline radiographic findings predict time to sputum
culture conversion in patients with MDR-TB and HIV, therefore,
remains unknown. The objective of the current study was to
examine this relationship in a group of patients with MDR-TB in
a rural area of South Africa with very high HIV seroprevalence.
Methods
Setting
Tugela Ferry is a resource-limited, rural area in KwaZulu-
Natal (KZN) province, South Africa with a population of
approximately 160,000 Zulu people. The case notification rate
of TB is over 1,100 per 100,000 population and MDR-TB
incidence was 118 per 100,000 in 2007 [2]. HIV prevalence
among women seeking antenatal care is estimated at 37%.
Patients with suspected or confirmed MDR-TB are referred to a
regional, decentralized specialty center for further evaluation
and treatment [14]. Since 2005, routine mycobacterial culture
and drug-susceptibility testing (DST) has been available for all
TB suspects in Tugela Ferry. This differs from other district
hospitals in South Africa, and from that recommended by
national policy, which reserves culture and DST for patients
who are either being re-treated for TB, or who are failing first-
line therapy [15].
Patients were treated with a standardized regimen of
kanamycin, ofloxacin, ethionamide, ethambutol, pyrazinamide,
and cycloserine (intensive phase) for 4 months following
culture conversion (defined as two consecutive negative
cultures at least one month apart) and a minimum of 6 months.
This regimen was continued, without kanamycin, for an
additional 18 months (continuation phase). Medications were
dosed by weight and modified in response to severe adverse
effects. Third-line TB drugs and surgical treatment were not
used. Patients with resistance to either a fluoroquinolone or
one of the second-line injectable medications (kanamycin,
amikacin, or capreomycin) were transferred to the TB referral
hospital in Durban and were not eligible for this study.
Most patients were hospitalized briefly to initiate MDR-TB
therapy and were then discharged to continue treatment on an
ambulatory basis. Patients were seen monthly at the
decentralized MDR-TB clinic and sputum cultures were
performed monthly throughout the course of treatment.
Sputum smears were examined with auramine fluorescent
microscopy. After decontamination, sputum was inoculated in
one mycobacteria growth indicator tube (MGIT) broth and on
one Middlebrook 7H10 agar plate. The broths were incubated
at 37°C in an automated incubator. Agar plates were sealed in
CO2-permeable plastic bags and incubated in 5% CO2 at 37°C.
Acid-fast microscopy was done on each positive MGIT broth.
Those containing acid-fast bacilli were subcultured on
Middlebrook 7H10 agar. Primary Middlebrook agar plates were
read weekly for 3 weeks or until growth was observed.
Microscopy was done to confirm the presence of acid-fast
bacilli and all positive cultures were identified as M.
tuberculosis by means of niacin and nitrate reductase tests.
Beginning in 2008, the hospital in Tugela Ferry began
routinely scanning chest radiographs for all patients with TB.
Using an EPSON 10000XL photographic and document
scanner with transparency attachment, radiographs were
scanned at a minimum of 350 dpi, in 16 bit black and white,
using SilverFast EpsonIT8 software (Vers. 6.6.0r5) by Laser
Soft Imaging.
Population
Patients were eligible for inclusion in the study if they (1) had
culture-confirmed pulmonary MDR-TB, (2) initiated MDR-TB
therapy at the regional referral center and (3) had a scanned
copy of their baseline posterior-anterior or anterior–posterior
chest radiograph, taken prior to the initiation of MDR-TB
therapy. When patients had multiple scanned radiographs on
file, we selected the one performed as close as possible to
treatment initiation, up to a maximum of 90 days prior.
Chest radiograph analysis
Radiographs were interpreted by a single chest radiologist
(B.Z.) who was blinded to the subjects’ clinical/demographic
characteristics and treatment outcome. A standardized case
report form was used to document the presence of cavities,
consolidation, nodules, hilar lymph node enlargement,
mediastinal lymph node enlargement, pleural effusion, pleural
calcification, volume loss, and miliary disease. The location of
any cavities or consolidation was specified by dividing the
lungs into six zones (upper/middle/lower for each lung). If hilar
lymph nodes were enlarged, the presence of unilateral or
bilateral enlargement was noted. As a quality check, the
primary radiologist read each film a second time, two weeks
after the initial read, blinding himself to his original
interpretation. All of these reads were concordant with the
earlier interpretation. Any questionable findings were reviewed
by a second radiologist (L.B.H.).
Radiographic Findings in MDR-TB/HIV Co-Infection
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Radiograph scoring
A cavity score and a consolidation score were each
generated as follows: 0 = no cavity/consolidation present;
1=cavity/consolidation present in one lung zone; 2=cavity/
consolidation present in at least two lung zones (unilateral or
bilateral). Similarly, we created a score for hilar
lymphadenopathy wherein 0 = no lymphadenopathy; 1 =
unilateral; 2 = bilateral.
Outcome scoring
Many patients suspected of having MDR-TB are placed on
first-line TB treatment while awaiting the results of sputum
culture and drug-susceptibility testing. As a result, although the
initial culture may demonstrate MDR-TB, some of these
patients have a negative repeat culture by the time they initiate
MDR-TB treatment (possibly due to activity of ethambutol
and/or pyrazinamide). We hypothesized that patients who
convert their culture in this manner have less severe disease
than those who are still culture-positive when they start MDR-
TB treatment. We therefore created an ordinal culture
conversion score in which 0 = conversion before MDR-TB
treatment initiation; 1 = conversion within 60 days of initiating
MDR-TB treatment; 2 = conversion after 60 days of initiating
MDR-TB treatment, or no conversion at all. Time to conversion
was defined as the number of days from initiation of MDR-TB
therapy to the first of two negative cultures taken at least one
month apart. The cut-point of 60 days was chosen because this
was the median time to culture conversion seen both in our
prior study of MDR-TB/HIV co-infection and in the HIV-negative
literature [12,16].
Statistical analysis
We used frequency analysis and chi-square testing to
identify associations between clinical characteristics and
radiographic findings. We examined the association of each of
four radiographic findings (cavity score, consolidation score,
effusion (yes/no) and hilar lymph node score) with the outcome
of culture conversion score. We used a log-linear regression
model assuming a multinomial distribution with a cumulative
logit link function in which the primary predictor variable was
the radiographic finding (e.g., cavity score) and the dependent
variable was the culture conversion score. We adjusted each of
the models for three clinical variables: HIV status, baseline
sputum acid-fast bacilli (AFB) smear (positive/negative) and
baseline CD4 count (≤50, 51-200, and >200 cells/mm3; at the
time of MDR-TB treatment initiation).
The study was approved by the Institutional Review Boards
at Albert Einstein College of Medicine, the University of
KwaZulu-Natal, and Yale University, and by the KwaZulu-Natal
Department of Health. The requirement for informed consent
was waived by the IRBs listed above, as all patient data had
been previously collected during the course of routine medical
care and the study did not pose any additional risks to the
patients.
Results
Between February 2008 and May 2010, 97 patients from
Tugela Ferry with culture-confirmed MDR-TB initiated therapy
at the decentralized MDR-TB clinic. Of these, 56 (58%) had an
available, scanned copy of their baseline chest radiograph
(Figure 1). Patients with available radiographs did not differ
from those without radiographs with respect to age, gender,
HIV status, CD4 count, receipt of antiretroviral therapy (ART),
or smear status (data not shown). Thirty-three (59%) patients
were female and the median age was 36 (IQR 30-42) years.
Forty-nine (88%) patients were HIV-positive with a median CD4
count of 136 cells/mm3 (IQR 65-249) at the time of MDR-TB
treatment initiation. Of those who were HIV-positive, 40 (82%)
were already receiving ART at the time of MDR-TB initiation
and an additional 6 (12%) started ART during MDR-TB
therapy. Thirty two (57%) patients were sputum AFB smear
positive and 24 (43%) patients had been previously treated for
TB (Table 1).
Radiographic findings
Radiographs were taken a median of 2 days (IQR 2-6) prior
to initiating MDR-TB treatment and no radiographs preceded
receipt of first-line TB treatment. Only one patient had a normal
chest radiograph. Twenty-two (39%) patients had a cavity, of
whom 6 (27%) had cavities in more than one lung zone (Table
2). Of those with cavities, 20 (91%) had an upper lobe cavity
and 15 (68%) had cavities exclusively in the upper lobes. Thirty
seven (66%) patients had pulmonary consolidations, of whom
23 (62%) had consolidations in more than one lung zone. Hilar
lymphadenopathy was common, and of the 40 (71%) patients
with enlarged hilar lymph nodes, 16 (40%) had bilateral
enlargement. Nineteen (34%) patients had pleural effusions.
Among patients with a CD4 count ≤50 cells/mm3, all had hilar
lymphadenopathy and none had cavities. Additional
radiographic findings are shown in Table 2.
Sputum culture conversion
Thirteen (23%) patients had a negative sputum culture at the
time of MDR-TB treatment initiation (Table 3). Eighteen (32%)
patients converted their culture within 60 days and 25 (45%)
either converted their culture after 60 days or not at all. In
bivariate analysis of each radiographic feature with culture
conversion score (0, 1, or 2), cavity score was associated with
longer time to culture conversion (OR 2.17; CI 1.29-3.64), as
was consolidation score (OR 1.60; CI 1.11-2.32) (Table 4). We
found no association, however, between presence of pleural
effusion (OR 1.12; CI 0.59-2.11) or hilar lymph node
enlargement (OR 1.35; CI 0.91-2.02) and time to culture
conversion. Positive sputum smear was associated with longer
time to conversion (OR 3.93; CI 1.92-8.07) but neither HIV
status nor CD4 count were associated with time to conversion.
In addition, while positive sputum smear was strongly
associated with cavity score (Fisher’s Exact Test p=0.005), we
found no association between positive sputum smear and
either HIV status (p=0.69) or CD4 count (p=1.0).
After adjusting for baseline sputum smear, HIV status, and
CD4 count, neither cavity nor consolidation score were
Radiographic Findings in MDR-TB/HIV Co-Infection
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Figure 1.  Chest radiograph showing left-sided pleural effusion, consolidation and both hilar and mediastinal
lymphadenopathy.  
doi: 10.1371/journal.pone.0073975.g001
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significantly associated with longer time to conversion although
there remained weak evidence of an association between
cavity score and culture conversion. In this multivariate model,
positive baseline sputum smear remained strongly and
independently associated with later culture conversion, but we
found no such association for HIV or CD4 count.
Table 1. Patient baseline characteristics (n=56).
CHARACTERISTIC N (%)
Female 33 (59)
Median Age, years (IQR) 36 (30-42)
Sputum Smear AFB-positive 32 (57)
Previous TB* 24 (43)
Previous MDR treatment 2 (4)
BMI†, median (IQR) 17.7 (16.1-21.6)
HIV-positive 49 (88)
Baseline CD4 available (% of HIV-positive) 42 (86)
Median baseline CD4, cells/ul (IQR) 136 (65-249)
On ART at time of MDR-TB treatment initiation (% of HIV-
positive)
40 (82)
Days on ART at time of MDR-TB treatment initiation, median
(IQR)
75 (3-181)
Started on ART during MDR-TB treatment (% of HIV-positive) 6 (12)
BMI: body mass index; IQR: interquartile range; ART: antiretroviral therapy
*. Does not include first-line treatment for current TB episode prior to diagnosis of
MDR-TB
†. Baseline height and weight only available for 32 patients







(n=7) N (%) p-value*
Cavity 22 (39) 16 (33) 6 (86) 0.01
One lung zone, (% of
those with cavity)
16 (73) 11 (69) 5 (83)  
Two or more lung zones
(unilateral or bilateral)
6 (27) 5 (31) 1 (17)  
Consolidation 37 (66) 32 (65) 5 (71) 1.0
One lung zone, (% of
those with consolidation)
14 (38) 13 (41) 1 (20)  
Two or more lung zones
(unilateral or bilateral)
23 (62) 19 (59) 4 (80)  
Pleural Effusion 19 (34) 18 (37) 1 (14) 0.40
Hilar lymph nodes 40 (71) 36 (73) 4 (57) 0.39
Unilateral 24 (60) 21 (58) 3 (75)  
Bilateral 16 (40) 15 (42) 1 (25)  
Calcified Lymph nodes 22 (39) 19 (39) 3 (43) 1.0
Volume loss/collapse/
bronchiectasis
32 (57) 27 (55) 5 (71) 0.68
Pleural calcification 6 (11) 6 (12) 0 (0) 1.0
Miliary Disease 2 (4) 2 (4) 0 (0) 1.0
Mediastinal lymph nodes 41 (73) 36 (73) 5 (71) 1.0
*. 2-tailed Fisher’s exact test.
Treatment Outcomes
Final treatment outcomes were available for all 56 patients
and of these, 44 (79%) were cured, four (7%) died, 3 (5%)
defaulted, 1 (2%) failed therapy and 4 (7%) were transferred to
the provincial TB specialty hospital in Durban (Table 3). We
performed bivariate logistic regression to identify predictors of
treatment success (defined as cure or treatment completion).
We found no association between the radiographic findings,
HIV status, smear status or CD4 count and final treatment
outcome.
Discussion
This study, which examined the relationship between
baseline chest radiographic findings and time to sputum culture
conversion in MDR-TB, has several important findings. Despite
extensive pathology on baseline chest radiograph, and
advanced immunodeficiency in the majority of patients, MDR-
TB treatment outcomes were favorable in this cohort. All but
three patients (5%) achieved culture conversion and 79% of
patients were cured at the end of treatment. Median time to
culture conversion was 66 days, which is similar to our earlier
published findings as well as reports in the HIV-negative MDR-
TB literature [12,16].
Although the presence and degree of cavitary disease on
baseline chest radiograph was associated with a longer time to
culture conversion in MDR-TB in bivariate analysis, this effect
did not retain statistical significance after adjusting for baseline
sputum smear status. In the multivariate model, smear status
was the only independent predictor of culture conversion,
suggesting that smear-positivity—which reflects bacillary
burden in the lung—may mediate the effect of cavitation on
time to culture conversion in our analysis. Other studies have
examined the prognostic significance of cavitary disease and
have found an inverse relationship with likelihood of culture
conversion [5,17]. To our knowledge, however, this is the
largest radiographic study of MDR-TB/HIV co-infection in the
ART era.
Table 3. Culture conversion and treatment outcomes.
CULTURE CONVERSION N (%)
Converted sputum culture to negative 53 (95)
Converted culture prior to initiation of second-line regimen 13 (23)
Converted while receiving second-line regimen 40 (71)
Median days to culture conversion (IQR)* 66 (43-96)
TREATMENT OUTCOMES  
Final Outcome reached 56 (100)
Cured 44 (79)
Died 4 (7)
Transferred Out 4 (7)
Defaulted 3 (5)
Treatment failure 1 (2)
IQR: interquartile range
*. Measured from date of MDR-TB treatment initiation to the first of two negative
sputum cultures taken at least one month apart.
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Several studies have shown that radiographic findings from
TB differ between patients with and without HIV [7,8,18–20].
Perlman et al. found that severity of immunosuppression from
HIV was inversely associated with the presence of cavities on
chest radiograph in patients with drug-susceptible TB [21]. Only
10% of patients in their cohort had cavitary disease, but those
with CD4 <200 cells/mm3 were significantly less likely to have
cavities and more likely to have hilar/mediastinal
lymphadenopathy. We found a similar relationship between
CD4 count and radiographic findings; all of the patients with a
CD4 count ≤50 cells/mm3 had hilar lymphadenopathy and none
had cavities. Overall, however, a greater proportion of our
patients (39%) had cavitary disease compared to those
reported by Perlman. Angthong et al. also found a higher
prevalence of cavitary disease among Japanese HIV-infected
patients with a CD4 count >200 cells/mm3 and drug-susceptible
TB, but their study population only included 5 patients with a
high CD4 count [22]. Fishman et al., by contrast, found no
difference in the presence of cavities between patients with a
CD4 count greater than, versus less than 100 cells/mm3 [23].
We found no association between CD4 count and location of
cavity, but our analysis was limited by small numbers within the
subgroups.
In their study from New York in the mid-1990’s, Telzak et al.
found that cavitary disease and baseline smear, but not HIV,
were associated with a prolonged time to culture conversion
[17]. This cohort was a mix of drug-susceptible and MDR-TB
cases, but similar to our population, most had no history of
prior TB treatment. Investigators in Spain found that HIV
infection was associated with less frequent cavitary disease
and a shorter time to sputum smear conversion, but the
authors did not report CD4 counts [11]. They, too, found that
Table 4. Association of radiographic findings and clinical














Cavity Score† 2.17 1.29-3.64 1.79 0.94-3.42
Consolidation Score‡ 1.60 1.11-2.32 1.09 0.67-1.78
Pleural effusion 1.12 0.59-2.11 − −
Hilar lymphadenopathy 1.35 0.91-2.02 − −
HIV 0.83 0.32-2.15 1.83 0.60-5.58
Baseline sputum smear 3.93 1.92-8.07 3.45 1.39-8.59
CD4 group§ 1.16 0.74-1.82 1.21 0.71-2.08
*. Culture conversion score: 0 = conversion prior to initiation of MDR-TB treatment;
1 = conversion within 60 days of initiating MDR-TB treatment; 2=conversion >60
days after initiating MDR-TB treatment OR lack of culture conversion.
†. Cavity score: 0 = no cavity; 1 = cavity in one lung zone; 2 = cavity in >1 lung
zone.
‡. Consolidation score: 0 = no consolidation; 1 = consolidation in one lung zone; 2
= consolidations in >1 lung zone.
§. CD4 groups: ≤50, 51-200, and >200 cells/mm3; HIV-negative subjects were
included in the highest CD4 group.
Bold: p<0.05
the presence of cavities on chest radiograph was associated
with a prolonged time to sputum smear conversion, consistent
with our findings. We suspect that the unifying mechanism
relating HIV infection, cavitary disease and sputum culture
conversion is the lung bacillary burden, as indicated by the
sputum smear. HIV co-infected patients with higher CD4
counts are more likely to develop cavitary disease and are thus
more likely to have a high bacillary burden [24] and to be
sputum smear-positive at baseline [25]. This, in turn, prolongs
the time to culture conversion when receiving therapy but does
not necessarily predict poor final treatment outcomes.
Our findings must be taken in the context of the local drug-
resistant tuberculosis epidemic. In studies from several
countries, the MDR-TB subjects had received multiple courses
of TB, and even MDR-TB therapy [12,26–28]. Our population,
by contrast, was not heavily treatment-experienced. We have
previously shown that the epidemic in Tugela Ferry has been
driven primarily by transmission—often in the hospital setting
[29]—and consistent with these earlier findings, the majority of
subjects in this study had never been previously treated for TB.
In light of this evidence suggesting recent, primary MDR-TB
infection, high rates of HIV co-infection and low CD4 counts,
the extensive pathology seen on chest radiographs in this
cohort is surprising.
This study has several limitations. First, we did not have
radiographs from a control population of drug-susceptible TB
patients for comparison. Nevertheless, when compared to
other studies in patients with drug-susceptible TB or MDR-TB
but without HIV co-infection, our findings shed further light on
the interplay between TB disease, drug-resistance, HIV
infection and radiographic findings. Second, our sample size
was small, and the borderline significance of the association
between cavitary disease and time to conversion may reflect a
lack of power. With a larger sample size, this association—
which was significant on bivariate analysis—may have retained
significance in the adjusted model. Similarly, the number of
HIV-negative subjects in our cohort was also very small,
limiting our ability to examine independent effects of HIV-
infection. A third limitation is that follow-up radiographs were
not available for most patients, and as a result, we were unable
to examine how changes in radiographic findings during
treatment might correlate with, or predict clinical course and
culture conversion. Fourth, because a majority of patients
initiated ART several weeks prior to starting MDR-TB therapy,
we were unable to exclude the possibility that some
radiographic findings represented immune reconstitution
inflammatory syndrome (IRIS). Finally, post-treatment
surveillance results are not available, and it is possible that
patients with extensive cavitary disease and longer time to
culture conversion may be at higher risk of relapse after “cure.”
Future studies are needed to answer this question and to
determine if such patients should receive a prolonged intensive
phase, prolonged continuation phase, or other modification in
treatment.
The results of our study suggest that the presence of cavities
on baseline chest radiograph is associated with prolonged time
to sputum culture conversion. This relationship is likely
mediated by a high bacillary burden in the lung and positive
Radiographic Findings in MDR-TB/HIV Co-Infection
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sputum smear for AFB. The presence and degree of
lymphadenopathy and pleural effusions in this cohort were not
associated with time to culture conversion. Chest radiographs
remain a useful clinical tool for monitoring response to therapy
and diagnosing the immune reconstitution inflammatory
syndrome, and a baseline radiograph should be obtained in all
patients for later comparison. As a predictive tool in this South
African population, however, radiographs may not have an
independent association with time to sputum culture conversion
beyond that of baseline sputum smear status.
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